Accuitis, Inc.
🇺🇸United States
Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea
Phase 2
Completed
- Conditions
- Acne Rosacea
- Interventions
- Drug: ACCU-D1Drug: Vehicle
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Accuitis, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03064438
- Locations
- 🇺🇸
DS Research, Louisville, Kentucky, United States
🇺🇸DermResearch, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath